MDM4 (GeneName), Protein Mdm4 (ProteinName), MDM4_HUMAN.
Product Name:
Human MDM4/ Protein Mdm4 ELISA Kit
Cat.#:
E12870h
Brand:
EIAab®
Regulatory Status:
Alternative:
Double minute 4 protein, Mdm2-like p53-binding protein, Protein Mdmx, p53-binding protein Mdm4, MDMX
Detection Method:
ELISA
Assay Type:
Sandwich
Detection Range:
0.78-50ng/mL
Sensitivity:
0.44ng/mL
Specificity:
Natural and recombinant human Protein Mdm4
Sample Type:
Serum, plasma, tissue homogenates, cell culture supernates and other biological fluids
Sample Data:
Assay Procedure:
Research Area:
Cancer
- Data
- Citations
- Publication
- Sequence / 3D
- Feedback Wall (0)
General Annotation
Sub Unit:
Interacts with MDM2, TP53, TP73 and USP2. Found in a trimeric complex with USP2, MDM2 and MDM4. Interacts (phosphorylated) with YWHAG; negatively regulates MDM4 activity toward TP53.
Function:
Inhibits p53/TP53- and TP73/p73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Inhibits degradation of MDM2. Can reverse MDM2-targeted degradation of TP53 while maintaining suppression of TP53 transactivation and apoptotic functions.
Subcellular Location:
Nucleus
Database links
Valid Sequence:
This product has not yet been referenced specifically in any publications.
[1].
"Isolation and identification of the human homolog of a new p53-binding protein, Mdmx."
[3].
"14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation."
[4].
"ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage."
[5].
"The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans."
[6].
"Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score."
[7].
"Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations."
[8].
"Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study."
[9].
"An approach based on a genome-wide association study reveals candidate loci for narcolepsy."
[10].
"MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer."
Feedback Wall
Displaying results : 0
All customer
All customer
Default sort
Default sort
Newest first
Oldest first
No feedback yet, let's comment.
Message
Product Name *
Email *
Message: *
Inform
Size
Quantity
Price ($)
Subtotal 1 ($)
Subtotal 2:
$
Size
Quantity
Price ($)
Discount:
Please select at least one unit!
Do you want to be our agent and get a lower discount?
Please contact us:
Tel:
Fax:
Email:sales@eiaab.com
Please contact us:
Tel:
Fax:
Email:sales@eiaab.com